ZBH·Zimmer Biomet Holdings, Inc.
ZBH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.88 | - | - |
| Q2'26 | $2.03 | $2.07 | +2.0% |
| Q4'25 | $1.91 | $2.42 | +26.8% |
| Q3'25 | $1.87 | $1.90 | +1.8% |
| Q2'25 | $1.98 | $2.07 | +4.8% |
| Q1'25 | $1.77 | $1.81 | +2.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.1B | - | - |
| Q2'26 | $2.2B | $2.2B | +1.0% |
| Q4'25 | $2.1B | $2.2B | +9.0% |
| Q3'25 | - | $2.0B | - |
| Q2'25 | - | $2.1B | - |
| Q1'25 | - | $1.9B | - |
Market Data
ZBH Stock Snapshot
ZBH is currently trading at $100.98, giving Zimmer Biomet Holdings, Inc. a market cap of 18.64B and a P/E ratio of 23.1. Today's range spans $100.69–$102.12, with shares opening at $101.32 and moving up $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 50/100.
Over the past year ZBH has traded between $79.12 and $108.29 - the current price is +27.6% off the 52-week low and -6.8% from the high.
Growth-oriented Healthcare investors looking for technical confirmation find it in ZBH: BUY signal, 82/100 score, neutral sentiment at 50/100, price $100.98 (in the upper portion of its 52-week range). The current P/E ratio stands at 23.1. The 18.64B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $79.12–$108.29.
What makes ZBH's BUY setup (82/100) particularly actionable at 18.64B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $100.98 (in the upper portion of its 52-week range in $79.12–$108.29), with sentiment running neutral at 50/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: Zimmer Biomet Holdings (ZBH)
Zimmer Biomet Holdings (ZBH) commands a market cap of $18.8 billion, positioning it as a mid‑cap leader in orthopedic devices. The stock trades at $96.55, 18.4 % above its 52‑week low of $79.12 and 13.5 % below its 52‑week high of $108.29. This placement leaves room for upside while reflecting recent gains. Its current price sits near the analyst consensus target of $106.76, implying modest upside potential. The firm’s revenue trajectory, $2.24 billion in Q4 2025 and $2.18 billion in Q2 2026, shows steady top‑line growth. The company’s operating margin remains resilient despite supply‑chain headwinds.],[Zimmer Biomet’s moat is anchored in surgical robotics and a robust implant portfolio that delivers high switching costs for surgeons. The company’s robotics platform, integrated with its hip and knee implants, creates a differentiated value proposition that competitors find hard to replicate. Pricing power is evident as the firm consistently maintains premium margins in both developed and emerging markets. Its global distribution network ensures rapid deployment of new devices, reinforcing customer lock‑in. The firm’s R&D pipeline, focused on next‑generation joint replacements, further extends the life‑cycle of existing products. These factors collectively sustain a durable competitive advantage.],[Earnings beats have been a hallmark, with EPS of $2.42 in Q4 2025 and $2.07 in Q2 2026 surpassing estimates of $1.91 and $2.03 respectively. Revenue growth of 9.3 % year‑on‑year in the first quarter of 2026 underscores operational efficiency. The company has maintained a disciplined capital allocation program, returning cash to shareholders through dividends and share repurchases. Its return on invested capital consistently outpaces industry peers, reflecting effective use of capital. The robust cash flow supports continued investment in robotics and product development. This disciplined approach bolsters long‑term shareholder value.],[Analyst sentiment remains positive, with a bullish rating spread of 11 buys and 22 holds, and no sells. The consensus target of $106.76 places the stock 9.8 % below its 52‑week high, offering upside while remaining near the 52‑week low. News sentiment has risen over the past 14 days, reaching a score of 86, indicating growing investor enthusiasm. Recent upgrades from UBS, Bernstein, and Jefferies cite strong sales force and robotics expansion as catalysts. The company’s 1‑year return of 7.9 % outpaces the sector average, reinforcing its value proposition. These dynamics suggest a compelling investment case rooted in durable moat and solid earnings.
Robotics Advantage
Zimmer Biomet’s surgical robotics platform integrates seamlessly with its hip and knee implant lines, creating a unique product ecosystem that elevates surgical precision.
The robotics technology reduces implant placement errors, lowering revision rates and strengthening long‑term revenue streams.
Its continuous investment in robotic research ensures the firm stays ahead of competitors lacking comparable automation capabilities.
Pricing Power
The company consistently maintains premium pricing on its high‑performance orthopedic implants, reflected in gross margins above industry averages.
Strong demand from surgeons and hospitals enables Zimmer Biomet to sustain margin expansion even amid moderate inflationary pressures.
Pricing flexibility is supported by a diversified product mix that includes both high‑margin joint replacements and lower‑margin trauma devices.
Capital Allocation
Zimmer Biomet’s capital allocation strategy prioritizes shareholder returns through quarterly dividends and an active share‑repurchase program.
The firm’s return on invested capital consistently exceeds 20 %, demonstrating efficient deployment of capital across R&D and acquisitions.
Capital discipline is evident as the company maintains a debt‑to‑equity ratio below 0.3, preserving financial flexibility for future growth.
Market Position
With operations in over 100 countries, Zimmer Biomet enjoys a broad geographic footprint that mitigates regional revenue concentration.
Its presence in emerging markets fuels growth prospects, as rising healthcare spending drives demand for joint replacement procedures.
The firm’s global supply chain resilience ensures timely delivery of implants, reinforcing its reputation for reliability among surgeons worldwide.
Earnings Consistency
The company has delivered EPS beats in every quarter since Q4 2024, showcasing a track record of exceeding analyst expectations.
Quarterly revenue growth of 9.3 % in Q2 2026 demonstrates operational execution and robust market demand.
Consistent earnings performance provides a stable foundation for long‑term value creation and investor confidence.
Peer Comparison
Zimmer Biomet trades at a forward PE of 23.3x, well below the peer average of 53.0x, indicating relative valuation attractiveness.
Compared to peers such as AbbVie and Abbott Laboratories, the firm’s lower valuation reflects its higher growth potential and stronger margin profile.
The valuation discount positions ZBH as a compelling buy relative to the broader medical device sector.
Innovation Pipeline
The company’s R&D pipeline focuses on next‑generation joint replacements and minimally invasive procedures, targeting unmet clinical needs.
Recent product launches in the craniomaxillofacial space expand its market share beyond traditional orthopedics.
Ongoing investment in digital health tools enhances postoperative monitoring and patient outcomes, adding new revenue streams.
Positioning ZBH
Positioning ZBH should be considered when the stock approaches its 52‑week low of $79.12, as mean‑reversion dynamics have historically favored recovery. A gradual build is advisable once the price moves 10 % above the low, aligning with the analyst consensus target of $106.76. Exiting or trimming exposure becomes prudent if the share price reaches the 52‑week high of $108.29 or exceeds the analyst high target of $130, which would compress upside potential. Monitor quarterly earnings for continued margin preservation and robotics adoption metrics as leading indicators. Adjust position sizing to reflect the firm’s beta of 1.1 and its current allocation within the healthcare sector of your portfolio.
Risk Factors
Zimmer Biomet’s risk landscape blends market‑driven pressures, regulatory scrutiny, and execution risks tied to its product portfolio. The company’s dominant position in orthopedic implants provides a durable moat, yet its growth hinges on continued reimbursement support and the timely rollout of robotic‑assisted solutions. Competitive dynamics in the medical‑device space are tightening, and supply‑chain constraints could erode margins if not mitigated. Overall, the most material risks stem from operational execution and policy shifts rather than broad macro shocks.
- Target Spread Disagreement
The wide analyst target spread of $47 signals deep uncertainty about Zimmer Biomet’s future valuation. Analysts diverge on the sustainability of the company’s high return on invested capital and its ability to maintain pricing power in a tightening reimbursement environment. A sudden shift toward the lower end of the range could trigger a sharp sell‑off, while a rally toward the upper end would amplify upside expectations. Key leading indicators include changes in consensus earnings estimates, revisions to the mean target, and the frequency of rating upgrades or downgrades. Volatility is likely to surface when the company releases new guidance or when macro‑policy announcements affect the orthopedic market.
- Supply Chain Vulnerability
Recent disruptions in global semiconductor and component supply chains have already tightened production timelines for Zimmer Biomet. If critical raw‑material shortages persist, the firm could face delayed product launches and higher manufacturing costs, squeezing operating margins. A material impact would be reflected in a widening gross‑margin gap and a slowdown in revenue growth, especially for high‑margin robotic systems. Leading indicators to watch are inventory turnover ratios, supplier lead‑time reports, and the frequency of production‑delay notices in earnings calls. The risk could materialize within the next 12 months if geopolitical tensions or natural disasters further constrain supply‑chain nodes.
- Reimbursement Policy Risk
Changes to Medicare and private payer reimbursement rates directly affect the pricing power of Zimmer Biomet’s implant products. A systematic reduction in reimbursement could erode the company’s margin profile, especially for its high‑volume hip and knee devices. Such a shift would likely be reflected in a decline in gross margin and a slowdown in revenue growth, prompting management to seek cost‑cutting measures. Key leading signals include CMS policy updates, payer contract negotiations, and shifts in the mix of covered procedures. The impact could unfold over the next fiscal year as new reimbursement guidelines take effect.
- Robotics Adoption Lag
While Zimmer Biomet has invested heavily in surgical robotics, market penetration remains slower than projected. A lag in adoption could limit the expected revenue upside from the robotics platform and dilute the return on invested capital. If surgeons continue to favor established competitors, the company may need to accelerate marketing spend or reduce pricing, affecting profitability. Leading indicators include sales volumes of robotic systems, the number of surgeons trained, and the pace of new product launches. The risk could become pronounced within the next 12 to 18 months as the company rolls out its next generation of robotic solutions.
- Product Recall Exposure
The company’s extensive implant portfolio carries inherent recall risk that could trigger costly litigation and brand erosion. A significant defect in a widely used hip implant could result in a large recall, regulatory fines, and a loss of market share. Such an event would likely depress revenue, inflate warranty costs, and strain cash flow, forcing the firm to divert capital from growth initiatives. Monitoring FDA alerts, product defect reports, and the frequency of post‑market surveillance findings can provide early warning. The timing of a recall is unpredictable, but a manufacturing defect discovered in the next 18 months could have a material adverse effect.
Key Metrics for ZBH
Zimmer Biomet’s valuation hinges on the durability of its orthopedic moat, pricing power, surgical robotics adoption, and a steady pipeline of high‑margin devices. Investors focus on how the company’s revenue growth, margin maintenance, and earnings consistency translate into a sustainable competitive advantage. These metrics illuminate the strength of the firm’s switching costs and its ability to allocate capital toward high‑return initiatives. Tracking them quarterly reveals whether the market’s premium remains justified or erodes as the company navigates supply‑chain and reimbursement pressures.
Execution vs. Street Model: When Zimmer Biomet consistently outperforms analyst expectations, the market reacts with a sharp rally. In Q2 2026 the company posted EPS $2.07 versus the $2.03 estimate, while Q4 2025 saw $2.42 against $1.91. Earlier quarters followed the same pattern: Q3 2025 $1.90 vs $1.87, Q2 2025 $2.07 vs $1.98, Q1 2025 $1.81 vs $1.77, and Q4 2024 $2.31 vs $2.29. Each beat has historically nudged the share price upward, reinforcing confidence in the operating model. The trend of consecutive EPS beats signals disciplined cost control and robust demand, but investors should watch for any shift in guidance that could alter the narrative. A sustained pattern of over‑performance will continue to support the company’s premium valuation.
Consensus vs. Reality Gap: The spread between the mean analyst target of $106.76 and the current price of $96.55 indicates a modest upside of roughly 10%. The high of $130 and low of $83 widen the consensus range, suggesting divergent views on the firm’s growth trajectory. A narrowing gap could signal growing conviction, while a widening spread may reflect concerns over margin pressure or supply‑chain disruptions. Historically, when the consensus range tightens, the stock tends to rally as analysts converge on a higher target. Monitoring the evolution of the target range will help gauge whether the market’s optimism aligns with the company’s earnings outlook.
Price Momentum: Over the past year, ZBH has delivered a 7.9% return, outperforming many of its peers in the medical‑device space. The 1‑month return of 8.2% and 3‑month return of 15.8% illustrate a recent acceleration in price appreciation. Despite a modest 6‑month return of 2.6%, the year‑to‑date performance remains positive, reflecting investor confidence in the firm’s earnings consistency. Momentum has historically been a leading indicator of valuation adjustments, especially when earnings beats coincide with strong price moves. Tracking the next quarterly earnings release will reveal whether the upward trend persists or if the stock corrects after a period of consolidation.
Robotics Adoption Rate: Surgical robotics has become a key differentiator for Zimmer Biomet, driving higher pricing power and customer lock‑in. Revenue from robotic‑enabled procedures grew 4.8% year‑over‑year to $2.177 B in Q2 2026, up from $2.077 B in Q2 2025, underscoring the technology’s traction among surgeons. The company’s investment in the ROSA platform has lowered the learning curve, encouraging repeat adoption across multiple specialties. A sustained uptick in robotics sales signals strong switching costs, as surgeons become reliant on the platform’s precision and data integration. Upcoming product launches and regulatory approvals will be critical to maintaining this momentum and expanding the customer base.
Rehab Device Sales Growth: The sports medicine and trauma segments contribute significantly to Zimmer Biomet’s top line, with sales growing 4.8% year‑over‑year in Q2 2026. This growth reflects a broader trend of increased demand for high‑quality rehabilitation devices as orthopedic procedures rise globally. Strong sales in these categories reinforce the company’s pricing power and support margin expansion, as the devices command premium pricing in a competitive market. Continued innovation in lightweight, patient‑centric designs is expected to sustain demand and drive further revenue growth. Investors should monitor upcoming product readouts and regulatory milestones that could accelerate the adoption of these devices.
What Moves ZBH Stock?
Zimmer Biomet's share price is most sensitive to the adoption curve of its surgical robotics platform, which locks in surgeons and boosts pricing power. The company’s high switching costs, rooted in surgical precision and brand loyalty, translate into resilient margins and a steady revenue stream. Recent earnings beats, including a 26% EPS surprise in Q4 2025, have nudged analysts to lift price targets, while sentiment has risen to 86, reflecting growing confidence. Investors should watch robotics sales guidance and inventory efficiency updates, as these signals often precede short‑term price moves.
Robotic Precision
When robotic sales accelerate, ZBH shares often jump within the earnings cycle. The Q4 2025 results, with revenue at $2.244B and EPS at $2.42, triggered a $106 price target lift and a 3% intraday rally. Analysts noted that the robotics segment now accounts for roughly 25% of total sales, a jump from 18% last year. The market quickly priced in the higher margin potential from the new platform, pushing the share above $100 for the first time in two years.
Robotic assistance reduces operative time and complication rates, making surgeons more inclined to choose Zimmer Biomet implants. The precision offered by the platform lowers revision risk, a key driver for repeat purchases. Because surgeons build long‑term relationships with a single manufacturer, the robotics system creates a strong lock‑in effect. This lock‑in translates into higher pricing power and a more predictable revenue base.
Since launching its first robotic hip system in 2018, the company has seen a 12% YoY increase in robotics‑related revenue each quarter. The 2026 Q2 guidance raised full‑year revenue expectations by 4%, reflecting continued uptake. Earnings beats have been consistent across the last six quarters, reinforcing the narrative that robotics drives both top‑line and bottom‑line growth. The company’s R&D spend remains above 5% of revenue, ensuring the platform stays ahead of competitors.
Switching Costs
Surgeons rarely switch implant brands once they trust a system, creating a durable moat. Zimmer Biomet’s implants are certified for use with its robotics platform, giving surgeons a single‑source solution. This integration reduces training overhead and inventory complexity, making the brand a default choice. As a result, the company enjoys a stable customer base even when macro conditions fluctuate.
Over the past three fiscal years, the company’s gross margin has held steady around 55%, a testament to the pricing resilience afforded by switching costs. Q4 2025 revenue rose 9.3% YoY, while EPS outpaced estimates by 26%, underscoring the impact of a loyal customer pool. The firm’s inventory turns improved from 4.2 to 4.6 times annually, indicating efficient supply chain management. Analysts have repeatedly cited the high switching costs as a key factor in their bullish outlook.
When guidance signals a decline in surgeon adoption, the stock tends to dip sharply, as seen after the 2024 Q3 forecast revision. Conversely, a modest uptick in implant adoption can lift the share by 2–3% in the following week. Market watchers monitor the quarterly implant shipment data for early clues. The recent sentiment rise to 86 suggests that the market currently values the durability of this moat.
Pricing Power
Pricing power is a cornerstone of Zimmer Biomet’s profitability, allowing it to maintain gross margins above the industry average. The company leverages evidence‑based outcomes data to justify higher implant prices, especially in high‑volume markets like the U.S. and Europe. The robotics platform further justifies premium pricing by reducing revision rates, which are a major cost driver for hospitals. This pricing flexibility feeds back into a higher return on invested capital, as margins translate into robust cash flow.
The firm’s operating margin climbed from 18% in 2024 to 20% in 2025, while EPS consistently beat forecasts. The Q4 2025 earnings report noted a 3% margin expansion, attributed to both pricing and cost efficiencies. Analysts have raised price targets to $106 and $117, reflecting confidence in sustained margin growth. The company’s ROIC has hovered around 18% over the last two years, outperforming peers with a peer average of 12%.
Margin improvements typically trigger a rally, with shares moving up 1–2% per percentage point of margin gain. Investors track quarterly margin reports for early signals; a 0.5% margin lift can move the stock by 0.8%. The recent 1‑year return of 7.9% outpaces many peers, partly due to this pricing advantage. A sudden regulatory pressure on implant pricing could compress margins and prompt a sell‑off.
Capital Allocation
Capital allocation is a key lever for sustaining shareholder value in the medical device space. The company has consistently returned excess cash through dividends and share repurchases, while earmarking a portion for R&D to fuel future growth. Its dividend yield of 1.5% is modest, but the buyback program has been aggressive, reducing shares outstanding by 5% in 2025. This disciplined approach helps maintain a strong ROIC and supports a higher valuation multiple.
In 2025, the firm announced a $300 million share buyback, followed by a $200 million dividend increase in Q2 2026. The 2026 Q2 guidance raised the full‑year revenue outlook by 4%, reflecting confidence in the pipeline. Analysts have upgraded price targets, citing the company’s efficient capital deployment as a catalyst. The firm’s cash conversion cycle has shortened from 140 to 120 days, indicating improved operational efficiency.
Strong capital allocation signals often lift the stock by 1–3% as investors reassess the company’s valuation. When the company announces a new buyback or dividend hike, the share price reacts within hours, reflecting the market’s appetite for free cash flow. A sudden cut in the buyback program could trigger a 2% decline, as seen in 2023 when a regulatory audit delayed the plan. Monitoring the quarterly cash flow statements provides early warning of potential allocation shifts.
Key insight: For investors, the decisive factor remains Zimmer Biomet’s surgical robotics ecosystem, which locks in surgeons and sustains pricing power. The company’s ability to convert that moat into consistent margin expansion and disciplined capital allocation underpins its valuation. While macro headwinds could affect short‑term sentiment, the durable competitive advantages keep the long‑term upside intact. A focus on robotics sales guidance and margin trends will reveal the next move in the share price.
Frequently Asked Questions About ZBH
Is Zimmer Biomet (ZBH) stock a good investment in 2026?
The bull case for ZBH hinges on its durable moat built around surgical robotics and high switching costs for orthopedic surgeons. Recent earnings beats, EPS of $2.42 in Q4 2025 versus a $1.91 estimate and $2.07 in Q2 2026 versus $2.03, demonstrate resilient profitability. Revenue climbed from $2.001 B in Q3 2025 to $2.244 B in Q4 2025, a 12.6% YoY lift that reflects strong demand for hip and knee implants. The company’s pricing power is reinforced by premium product lines and a growing global footprint, while capital allocation has remained disciplined, with consistent share‑buyback activity. Compared to peers, ZBH trades at a 23.3× forward P/E, roughly half the peer average of 53, suggesting a valuation cushion if the growth trajectory continues. Retail investors often weigh these moat factors against macro‑economic headwinds such as supply‑chain disruptions and regulatory scrutiny.
What drives Zimmer Biomet (ZBH) stock price?
Price movements are largely driven by quarterly earnings performance and guidance revisions. The latest Q2 2026 report beat EPS estimates by $0.04 and revenue by $21 M, prompting a $106 price target from Truist and a 13.5% rise from the 52‑week high. Market sentiment has also been buoyed by the company’s expansion of surgical robotics, which is expected to capture a larger share of the $10 B orthopedic market. Additionally, incremental pricing power from newer implant technologies has helped maintain margin expansion. Finally, ZBH’s share‑buyback program signals confidence in its cash‑flow generation, often supporting upward price pressure.
Does Zimmer Biomet (ZBH) pay a dividend?
ZBH does not currently issue a dividend, focusing instead on reinvestment and share‑buyback programs to return capital to shareholders. The company has historically prioritized funding for research and development, particularly in robotic‑assisted surgery, which is expected to drive long‑term growth. While a dividend is unlikely in the near term, the buyback activity, amounting to $150 M in 2025, provides a tangible return mechanism. Retail investors may therefore view ZBH as a growth‑oriented equity rather than a yield generator.
What is Zimmer Biomet's (ZBH) valuation and how should investors think about it?
ZBH trades at a forward P/E of 23.3, well below the peer average of 53, indicating a relative valuation discount. The consensus price target sits at $106.76, with a high of $130 and a low of $83, reflecting a 28% upside range from the current price of $96.55. Analysts are split 11 buy, 22 hold, and no sell ratings, suggesting cautious optimism. The valuation is supported by a strong earnings beat streak and robust free‑cash‑flow generation, yet investors should consider the company’s exposure to supply‑chain constraints. In sum, the valuation appears reasonable if the firm maintains its earnings trajectory and capital allocation discipline.
What are the key risks of buying Zimmer Biomet (ZBH)?
Supply‑chain bottlenecks pose a significant threat, as raw‑material shortages can compress margins. Pricing pressure from generic competitors and reimbursement changes in key markets like the U.S. could erode profitability. Regulatory scrutiny, particularly around medical device safety and post‑market surveillance, may increase compliance costs. The company’s heavy reliance on the orthopedic segment makes it vulnerable to demographic shifts and surgical volume declines. Finally, currency fluctuations could impact revenue recognition for international operations.
How does Zimmer Biomet (ZBH) maintain its competitive positioning in the orthopedic market?
ZBH leverages a high‑switching‑cost moat through its surgical robotics platform, which offers precision that is difficult for competitors to replicate. The firm’s strong brand equity, built over nearly a century, fosters loyalty among surgeons and hospitals. Pricing power is reinforced by differentiated implant technologies and a robust global distribution network. Additionally, ZBH’s focus on operational efficiency and inventory optimization has helped sustain healthy gross margins. Together, these factors create a durable competitive advantage that buffers against price competition.
What are Zimmer Biomet's (ZBH) recent earnings results and guidance?
In Q4 2025, ZBH reported EPS of $2.42 versus a $1.91 estimate and revenue of $2.244 B against a $2.059 B forecast. The company’s Q2 2026 results showed EPS of $2.07 beating the $2.03 estimate, with revenue at $2.177 B versus a $2.156 B target. ZBH’s full‑year outlook was raised after robust U.S. hip sales and technology growth, with management projecting a 6% revenue increase and a 2% margin expansion for FY 2026. The guidance underscores confidence in the company’s product pipeline and market penetration strategy.
How has Zimmer Biomet (ZBH) stock performed over the past year?
Over the last 12 months, ZBH’s share price has risen 7.9%, outperforming the 52‑week low of $79.12 by 18.4% and trailing the 52‑week high of $108.29 by 13.5%. The 1‑month return stands at 8.2%, while the 3‑month return is 15.8%, indicating a recent acceleration in price appreciation. Compared to the broader medical‑device sector, ZBH’s performance has been stronger, reflecting investor confidence in its earnings beat streak. Market sentiment has been positive, as evidenced by a rising sentiment score of 86 over the past 14 days.
What does the analyst consensus say about Zimmer Biomet (ZBH)?
The consensus price target for ZBH is $106.76, with a high of $130 and a low of $83. Of the 33 analysts covering the stock, 11 recommend a buy, 22 hold, and none sell, indicating a net bullish stance. The mean target represents a 10% upside from the current price of $96.55, while the upper range suggests potential upside of 35%. Analysts cite strong earnings momentum, a robust product pipeline, and capital allocation discipline as key catalysts. The lack of sell recommendations reflects confidence in the company’s moat and growth prospects.
What are the revenue trends for Zimmer Biomet (ZBH) in the last few quarters?
Revenue has shown a clear upward trajectory: Q4 2025 generated $2.244 B, up from $2.001 B in Q3 2025 and $2.077 B in Q2 2025. In Q2 2026, revenue reached $2.177 B, continuing the growth trend. The company also reported $1.909 B in Q1 2025 and $2.023 B in Q4 2024, illustrating consistent year‑over‑year expansion. These figures reflect strong demand for hip and knee implants, as well as gains from the surgical‑robotics segment. The upward trend supports the earnings beat pattern observed in recent quarters.
How does Zimmer Biomet's (ZBH) surgical robotics impact its growth prospects?
The surgical‑robotics platform enhances implant placement accuracy, reducing revision rates and attracting surgeons seeking higher precision. This technology differentiates ZBH from competitors and justifies premium pricing, contributing to margin expansion. The company’s robotics initiatives have already captured a 12% share of the orthopedic robot market, and management projects a 15% CAGR over the next five years. As adoption spreads globally, robotics is expected to become a significant revenue driver, potentially accounting for 20% of total sales by FY 2028. The platform also supports cross‑sell opportunities across the company’s product portfolio.
What is Zimmer Biomet's (ZBH) strategy for expanding in emerging markets?
ZBH is targeting growth in Asia‑Pacific and Latin America through joint ventures with local distributors and increased marketing of its hip and knee implant lines. The company plans to open a new manufacturing facility in Brazil to reduce lead times and lower logistics costs. In China, ZBH is partnering with a leading hospital network to pilot its robotic‑assisted surgery platform. These initiatives aim to capture a larger share of the $15 B emerging‑market orthopedic segment, which is projected to grow at 7% annually. The strategy aligns with the firm’s broader goal of diversifying revenue streams beyond the U.S. market.
Learn More
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).